v3.26.1
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
3 Months Ended
Nov. 04, 2025
Nov. 03, 2022
Jun. 30, 2026
Jun. 30, 2025
Mar. 31, 2025
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Share purchase value       $ 2,441,000  
Share based compensation     $ 100,000 $ 200,000  
2026 Pre-funded Warrants [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Stock issued during the period, shares     95,000    
Restricted Stock Units (RSUs) [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Vesting period     5 years    
2013 Beyond Air Equity Incentive Plan [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Stock option shares authorized for issuance     84,000    
Number of shares available for grant       44,359  
Vesting period     4 years    
Expiration period     10 years    
Weighted average fair value of options granted     $ 7.48    
2013 Beyond Air Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Weighted average remaining service period     8 months 12 days    
2013 BA Plan [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Share based compensation     $ 200,000    
2013 BA EquityIncentivePlan [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Weighted average remaining service period     1 year 6 months    
Unrecognized stock-based compensation expense     $ 1,000,000.0    
2021 Beyond Cancer Ltd Equity Incentive Plan [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Stock option shares authorized for issuance   4,000,000      
Number of shares available for grant     1,771,250    
Vesting period     4 years    
Weighted average remaining service period     1 year    
Expiration period     10 years    
Number of additionl shares reserve for issuance   2,000,000      
Unrecognized stock-based compensation expense     $ 100,000    
2023 Neuro Nos Ltd Equity Incentive Plan [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Stock option shares authorized for issuance         1,725,000
Number of shares available for grant     446,149    
Weighted average remaining service period     6 months    
Unrecognized stock-based compensation expense     $ 100,000    
Purchase Agreement [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Share purchase value $ 20,000,000        
Shares available for resale 80,000   58,692    
Common stock minimum purchase amount $ 25,000        
Beneficial ownership limitation percentage 4.99%        
Price per share     $ 9.20    
Adjustments in additional paid in capital     $ 500,000